Natera, Inc. (NTRA)

In the bull case, oncology test penetration and women's health volume accelerate beyond consensus expectations, sustaining strong double-digit annual revenue growth through FY2028. Fixed-cost absorption across high-throughput laboratory facilities drives gross margin expansion toward 70% and enables GAAP operating profitability ahead of expectations by FY2027. Rolling MolDX coverage decisions for pending submissions deliver an estimated $150 to $200 ASP expansion, while international launch in Japan broadens geographic diversification. Capex normalizes rapidly toward maintenance levels, generating substantial positive FCFF.

• Revenue growth accelerates above 26.2% in FY2026 and exceeds 22% through FY2028 driven by rapid clinical adoption of Signatera in oncology
• Rolling MolDX coverage decisions deliver $150 to $200 ASP expansion over the next 12 to 18 months
• Sequencing automation efficiencies lift gross margins above 70% and operating margin reaches 18.0% by FY2030
• Capex normalizes toward baseline capital expenditure intensity, generating substantial positive free cash flow